Meridian Bioscience Inc. (VIVO) Position Held by Dean Investment Associates LLC
Dean Investment Associates LLC maintained its position in Meridian Bioscience Inc. (NASDAQ:VIVO) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 413,745 shares of the company’s stock at the end of the second quarter. Meridian Bioscience makes up approximately 1.0% of Dean Investment Associates LLC’s holdings, making the stock its 29th biggest holding. Dean Investment Associates LLC owned about 0.98% of Meridian Bioscience worth $5,710,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Arizona State Retirement System grew its holdings in Meridian Bioscience by 0.5% during the 2nd quarter. Arizona State Retirement System now owns 22,041 shares of the company’s stock valued at $347,000 after buying an additional 100 shares in the last quarter. Texas Permanent School Fund grew its holdings in Meridian Bioscience by 0.8% during the 2nd quarter. Texas Permanent School Fund now owns 30,813 shares of the company’s stock valued at $485,000 after buying an additional 258 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in Meridian Bioscience by 1.8% during the 1st quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the company’s stock valued at $237,000 after buying an additional 300 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its holdings in Meridian Bioscience by 3.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock valued at $157,000 after buying an additional 370 shares in the last quarter. Finally, RiverPoint Capital Management LLC grew its holdings in Meridian Bioscience by 2.9% during the 1st quarter. RiverPoint Capital Management LLC now owns 20,965 shares of the company’s stock valued at $289,000 after buying an additional 599 shares in the last quarter. 87.27% of the stock is owned by institutional investors and hedge funds.
In other Meridian Bioscience news, Chairman John A. Kraeutler bought 7,000 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The stock was purchased at an average price of $13.67 per share, for a total transaction of $95,690.00. Following the completion of the transaction, the chairman now owns 345,230 shares of the company’s stock, valued at approximately $4,719,294.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.30% of the company’s stock.
A number of research analysts have weighed in on the company. Zacks Investment Research lowered Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub lowered Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. Three research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $14.75.
Shares of Meridian Bioscience Inc. (NASDAQ VIVO) traded up 0.71% during mid-day trading on Wednesday, hitting $14.25. The stock had a trading volume of 22,871 shares. Meridian Bioscience Inc. has a 12 month low of $10.75 and a 12 month high of $19.85. The company has a market cap of $601.39 million, a PE ratio of 28.50 and a beta of 0.86. The stock’s 50-day moving average is $13.90 and its 200 day moving average is $14.14.
Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The firm had revenue of $50.14 million during the quarter, compared to analysts’ expectations of $49.13 million. During the same quarter last year, the business posted $0.21 earnings per share. The firm’s revenue was down 1.0% on a year-over-year basis. On average, equities research analysts forecast that Meridian Bioscience Inc. will post $0.67 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 17th. Investors of record on Monday, August 7th were given a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a dividend yield of 3.53%. The ex-dividend date of this dividend was Thursday, August 3rd. Meridian Bioscience’s dividend payout ratio is currently 98.04%.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.